Browse News
Filter News
Found 36 articles
-
Roger Perlmutter’s company announced the addition Thursday of myriad early- to mid-stage assets in the cancer and neurodegenerative disease spaces.
-
Eikon Therapeutics Builds Leading Clinical Development Organization with Appointment of Senior Team with Extensive Industry Expertise
6/1/2023
Eikon Therapeutics, Inc. today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review.
-
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
6/1/2023
IMPACT Therapeutics and Eikon Therapeutics today announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023.
-
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline
6/1/2023
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline.
-
Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists
6/1/2023
Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics.
-
CymaBay Names Harish Shantharam Chief Financial Officer
5/9/2023
CymaBay Therapeutics, Inc. announced that seasoned biopharma executive Harish Shantharam, CFA has joined the company as Chief Financial Officer.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
10/26/2022
Merck, known as MSD outside the United States and Canada, announced that the Merck board of directors has unanimously elected Robert M. Davis to serve as chairman of the board, effective Dec. 1, 2022.
-
Think Bioscience Raises $17M in Oversubscribed Seed Round to Develop Small Molecule Drugs that Hit Undruggable Proteins
8/18/2022
Think Bioscience has raised $17M in an oversubscribed Seed round led by Innovation Endeavors and Xora Innovation, with participation from AV8 Ventures, Buff Gold Ventures, and LiquidMetal Ventures.
-
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
-
Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.
-
Eikon Therapeutics Announces Lease for East Coast Base of Operations in New York City
7/21/2022
Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a lease with Alexandria Real Estate Equities, Inc.
-
Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area
6/16/2022
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters.
-
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
5/16/2022
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors
3/31/2022
Eikon Therapeutics Inc. today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
-
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
3/23/2022
Eikon Therapeutics, Inc. today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.
-
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.